Anavex Life Sciences Corp. (AVXL.OB) Contracts FORENAP for Clinical Trials of Their Alzheimer’s Drug
Swiss-based drug company Anavex Life Sciences Corp. announced today that they have selected FORENAP Pharma as the contract research organization for Phase 1 clinical trials of ANAVEX 2-73, the company's lead Alzheimer's drug candidate. FORENAP has been involved in pre-clinical and clinical research for 20 years and is renowned for its expertise in central nervous system studies, including Alzheimer's disease. FORENAP will perform study setup, protocol review, site monitoring and project management for the trials. Rudy Luthringer, CEO of FORENAP, said, “We look forward to running a high-quality and cost-effective program as Anavex works to confirm its pre-clinical findings in…